The popularity of medications including Ozempic and Wegovy has businesses scrambling to adapt to their thinner, less-hungry ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MariTide, AMGN's GLP-1 candidate, offers potential upside due to its long-lasting effects and less frequent dosing, potentially addressing current market shortages. Despite risks, Amgen's strong ...

As Con­gress con­sid­ers widen­ing Medicare’s cov­er­age of the bur­geon­ing class of weight loss med­ica­tions, a new study says fur­ther ex­pan­sion of el­i­gi­ble pa­tients ...

The company says the single-dose vials are 50% less expensive than the list price of all other incretin (GLP-1) medicines for obesity. The vials come in 2.5 and 5 mg single doses. A four-week ...

Study reveals that GLP-1 therapy increases visceral adipose tissue metabolism, significantly contributing to weight loss in individuals with obstructive sleep apnea. Study: GLP-1 therapy increases ...

Novo Nordisk's GLP-1 drugs like Ozempic and Wegovy are smash hits. However, another biotech is working on a few programs that could be far better. It has plenty of money, good preliminary results ...

However, to date, no clinical trial has specifically evaluated the efficacy of GLP-1 receptor agonists on morbidity and mortality in people with heart failure. Semaglutide was recently shown to ...